Integrated Diagnostics Holdings plc (IDGXF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 11.12 means the share price is 11.12 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $320M is the value of all shares combined. Beta 0.28: the stock has moved about 72% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerIntegrated Diagnostics Holdings plc (IDGXF) trades at $0.5513. Integrated Diagnostics Holdings plc (IDGXF) is a consumer healthcare company providing medical diagnostics services across Egypt, Jordan, Sudan, and Nigeria. Market cap: $320M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for IDGXF: IDGXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IDGXF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
IDGXF: 2/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Integrated Diagnostics Holdings plc (IDGXF) Healthcare & Pipeline Overview
Integrated Diagnostics Holdings plc (IDGXF) delivers diverse medical diagnostics across several African and Middle Eastern countries, operating a substantial network of labs. With a P/E ratio of 11.12 and a dividend yield of 2.87%, the company focuses on providing comprehensive testing services in developing healthcare markets.
What Is the Investment Thesis for IDGXF?
With a profit margin of 16.2% and a gross margin of 40.6%, IDGXF demonstrates solid profitability. The company's expansion in regions with increasing healthcare demands, such as Egypt, Jordan, Sudan, and Nigeria, positions it for sustained growth. Key catalysts include increasing healthcare expenditure in these regions and potential expansion into new markets. However, investors may want to evaluate risks associated with operating in emerging markets, including regulatory challenges and economic instability. The company's beta of 0.28 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
IDGXF Key Highlights
Market capitalization of $320M, reflecting the company's current valuation in the market.
- P/E ratio of 11.12, indicating the price investors are willing to pay for each dollar of earnings.
- Profit margin of 16.2%, showcasing the company's efficiency in converting revenue into profit.
- Gross margin of 40.6%, highlighting the profitability of the company's core services.
- Dividend yield of 2.87%, providing a return to investors through dividend payments.
Who Are IDGXF's Competitors?
IDGXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| APDN Applied DNA Sciences, Inc. | $5.62 | +31.62% | $7.26M | — |
| BDSX Biodesix, Inc. | $26.04 | -3.84% | $212M | — |
| BIAFW bioAffinity Technologies, Inc. | $0.45 | -24.62% | $16.0M | — |
| GENE Genetic Technologies Limited | $0.77 | 0.00% | $111M | — |
| MYGN Myriad Genetics, Inc. | $3.36 | +5.33% | $317M | — |
| PRE Prenetics Global Limited | $23.66 | -2.51% | $402M | 335-pillar |
| NEO NeoGenomics, Inc. | $17.26 | -1.99% | $444M | 345-pillar |
| STIM Neuronetics, Inc. | $3.03 | +0.66% | $211M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IDGXF's Key Strengths?
Extensive network of branch labs.
- Diverse range of diagnostic test offerings.
- Strong brand presence in key markets.
- Experienced management team.
What Are IDGXF's Weaknesses?
Concentration of operations in a limited number of countries.
- Exposure to political and economic instability in emerging markets.
- Dependence on third-party suppliers for reagents and equipment.
- Limited research and development capabilities.
What Could Drive IDGXF Stock Higher?
Potential expansion into new geographic markets in Africa and the Middle East.
- Increasing healthcare expenditure in existing markets (Egypt, Jordan, Sudan, Nigeria).
- Introduction of advanced diagnostic technologies to enhance service offerings.
- Strategic partnerships with healthcare providers to expand reach.
- Telemedicine and remote diagnostics initiatives to extend services to underserved areas.
What Are the Key Risks for IDGXF?
Political and economic instability in emerging markets.
- Increasing competition from local and international players.
- Changes in government regulations and healthcare policies.
- Fluctuations in currency exchange rates.
- Dependence on third-party suppliers for reagents and equipment.
What Are the Growth Opportunities for IDGXF?
- Expansion in Existing Markets: IDGXF can further penetrate its existing markets in Egypt, Jordan, Sudan, and Nigeria by expanding its network of branch labs and introducing new diagnostic services. The healthcare expenditure in these countries is steadily increasing, driven by population growth and rising awareness of preventive healthcare. By leveraging its established brand and infrastructure, IDGXF can capture a larger share of the growing diagnostic services market in these regions. This expansion can be achieved through strategic partnerships, acquisitions, and organic growth initiatives.
- Introduction of Advanced Diagnostic Technologies: IDGXF can enhance its service offerings by incorporating advanced diagnostic technologies, such as molecular diagnostics and genetic testing. These technologies enable more accurate and personalized diagnoses, leading to improved patient outcomes. The global market for molecular diagnostics is projected to reach $15 billion by 2028, driven by advancements in genomics and proteomics. By investing in these technologies, IDGXF can attract a wider range of patients and healthcare providers, further solidifying its market position.
- Strategic Partnerships with Healthcare Providers: IDGXF can forge strategic partnerships with hospitals, clinics, and other healthcare providers to expand its reach and enhance its service delivery. These partnerships can involve establishing on-site labs, providing diagnostic services to patients referred by healthcare providers, and collaborating on research and development projects. By integrating its services with the broader healthcare ecosystem, IDGXF can create a seamless patient experience and drive greater utilization of its diagnostic services.
- Telemedicine and Remote Diagnostics: IDGXF can leverage telemedicine and remote diagnostics technologies to extend its services to remote and underserved areas. Telemedicine enables patients to consult with healthcare providers remotely, while remote diagnostics allows for the collection and analysis of patient samples from a distance. By embracing these technologies, IDGXF can overcome geographical barriers and provide access to quality diagnostic services to a wider population. The telemedicine market is projected to reach $175 billion by 2026, driven by advancements in communication technologies and increasing demand for remote healthcare services.
- Expansion into New Geographic Markets: IDGXF can explore opportunities to expand its operations into new geographic markets, particularly in other African and Middle Eastern countries with similar healthcare needs and market dynamics. These markets offer significant growth potential, driven by increasing healthcare expenditure and a growing demand for quality diagnostic services. By leveraging its expertise and experience in developing markets, IDGXF can successfully replicate its business model in new regions and further diversify its revenue streams.
What Are IDGXF's Competitive Advantages?
- Extensive Network: Operates a large network of 452 branch labs, providing broad geographic coverage.
- Diverse Test Offerings: Provides approximately 2,000 different diagnostic tests, catering to a wide range of medical needs.
- Established Brand: Has a strong brand reputation in its key markets.
- Geographic Focus: Focuses on developing markets with high growth potential.
What Does IDGXF Do?
Integrated Diagnostics Holdings plc (IDGXF), established in 1979 and headquartered in Saint Helier, Jersey, is a consumer healthcare company focused on delivering a broad spectrum of medical diagnostic services. The company operates primarily in Egypt, Jordan, Sudan, and Nigeria, addressing the increasing demand for quality healthcare services in these regions. IDGXF offers approximately 2,000 diagnostic test services, encompassing various medical disciplines, including immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. These services are crucial for accurate disease detection, monitoring, and overall patient care. As of December 30, 2021, IDGXF managed a network of 452 branch labs, strategically positioned to enhance accessibility for patients across its operational geographies. The company's extensive network and diverse testing capabilities have solidified its position as a key player in the consumer healthcare market, particularly in regions with growing healthcare needs. IDGXF's commitment to providing comprehensive diagnostic solutions underscores its role in supporting healthcare providers and improving patient outcomes in the developing markets it serves.
What Products and Services Does IDGXF Offer?
- Provides a wide array of medical diagnostic services.
- Offers approximately 2,000 different diagnostic tests.
- Operates through a network of 452 branch labs.
- Services include immunology, microbiology, hematology, and endocrinology.
- Provides clinical chemistry, molecular biology, cytogenetics, and histopathology testing.
- Offers radiology services.
- Operates in Egypt, Jordan, Sudan, and Nigeria.
How Does IDGXF Make Money?
- Generates revenue by providing medical diagnostic testing services to patients.
- Operates a network of branch labs where patients can access testing services.
- Partners with healthcare providers to offer diagnostic services.
- Focuses on developing markets with growing healthcare needs.
What Industry Does IDGXF Operate In?
Integrated Diagnostics Holdings plc (IDGXF) operates within the medical diagnostics and research industry, a sector experiencing growth due to increasing healthcare needs and technological advancements. The global medical diagnostics market is projected to continue expanding, driven by factors such as aging populations, rising prevalence of chronic diseases, and growing demand for personalized medicine. IDGXF competes with other diagnostic service providers, including APDN, BDSX, BIAF, BIAFW, and GENE, striving to differentiate itself through its extensive network, diverse test offerings, and geographic focus on developing markets. The company's success depends on its ability to adapt to evolving market trends, maintain competitive pricing, and deliver high-quality diagnostic services.
Who Are IDGXF's Key Customers?
- Individual patients seeking diagnostic testing services.
- Hospitals and clinics requiring diagnostic support.
- Healthcare providers referring patients for testing.
- Corporate clients requiring employee health screenings.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 164 days ago
- ● No analyst coverage
- ● Reported in EGP, converted to USD
Financial Health
Integrated Diagnostics Holdings plc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Key Financial Metrics
Return on equity for Integrated Diagnostics Holdings plc stands at 38.8%, a gauge of how efficiently it converts shareholder capital into profit. IDGXF trades at a trailing price-to-earnings ratio of 11.12, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 0.9%, a gauge of the cash the business throws off relative to its market value. Its earnings yield is 9.4%, the inverse of the P/E and a quick read on earnings relative to price.
Integrated Diagnostics Holdings plc (IDGXF) Valuation Context
Valued at $320M, IDGXF is classified as a small-cap stock.
IDGXF Revenue & Earnings Trend
In Q1 FY2026, IDGXF generated $39.5M in top-line revenue, marking a sequential decrease of 0.0%. The company recorded net income of $8.3M, with diluted EPS of $0.01. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, IDGXF averaged $0.01 in diluted EPS.
Company Profile
Integrated Diagnostics Holdings plc operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Saint Helier, JE. The company is led by CEO Hend El Sherbini. IDGXF has traded publicly since 2019.
IDGXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Extensive network of branch labs.
- Diverse range of diagnostic test offerings.
- Strong brand presence in key markets.
- Experienced management team.
Bear Case
- Concentration of operations in a limited number of countries.
- Exposure to political and economic instability in emerging markets.
- Dependence on third-party suppliers for reagents and equipment.
- Limited research and development capabilities.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2026 | $40M | $8M | $0.01 |
| Q4 FY2025 | $40M | $6M | $0.01 |
| Q3 FY2025 | $43M | $8M | $0.01 |
| Q2 FY2025 | $34M | $5M | $0.01 |
Q1 FY2026 · filed 31 Mar 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from EGP at today's rate
IDGXF Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
IDGXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IDGXF.
Price Targets
Wall Street price target analysis for IDGXF.
IDGXF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IDGXF; grades run from A+ (80-100) to F (below 30).
Leadership: Hend El Sherbini
CEO
Hend El Sherbini serves as the CEO of Integrated Diagnostics Holdings plc, leading a workforce of 6309 employees. Her career reflects a deep understanding of the healthcare sector, particularly in diagnostics. She has been instrumental in guiding IDGXF's strategic direction and expansion across its operational regions. Her expertise spans healthcare management, business development, and operational efficiency, making her a key figure in the company's growth and success.
Track Record: Under Hend El Sherbini's leadership, Integrated Diagnostics Holdings plc has expanded its network of branch labs and broadened its range of diagnostic services. She has overseen the company's growth in key markets such as Egypt, Jordan, Sudan, and Nigeria. Her strategic decisions have contributed to IDGXF's solid financial performance, including a profit margin of 16.2% and a gross margin of 40.6%.
IDGXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Integrated Diagnostics Holdings plc (IDGXF) may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting or regulatory oversight, which increases the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies often have less stringent listing requirements, leading to greater variability in company quality and transparency.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of regulatory oversight and financial reporting requirements.
- Potential for price manipulation and fraud.
- Higher volatility compared to stocks listed on major exchanges.
- Information asymmetry due to limited disclosure.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with relevant regulations.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Established operations in multiple countries (Egypt, Jordan, Sudan, Nigeria).
- Significant number of employees (6309).
- Long operating history (founded in 1979).
- Provision of essential healthcare services.
- Presence of a CEO (Hend El Sherbini).
IDGXF Healthcare Stock FAQ
Is IDGXF a good stock?
Stock Expert AI does not rate IDGXF buy, sell or hold. Integrated Diagnostics Holdings plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about IDGXF stock?
Analyst sentiment on Integrated Diagnostics Holdings plc (IDGXF) is pending further analysis, as indicated by the AI analysis. Key valuation metrics to consider include the company's P/E ratio of 11.12, profit margin of 16.2%, and gross margin of 40.6%.
What are the key factors to evaluate for IDGXF?
Evaluate IDGXF on fundamentals, analyst consensus, and risk factors. P/E: 11.12x vs the S&P 500's ~20-25x. With a profit margin of 16.2% and a gross margin of 40.6%, IDGXF demonstrates solid profitability. Not financial advice.
How frequently does IDGXF data refresh on this page?
IDGXF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven IDGXF's recent stock price performance?
Integrated Diagnostics Holdings plc (IDGXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive network of branch labs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IDGXF overvalued or undervalued right now?
Integrated Diagnostics Holdings plc (IDGXF) trades at 11.12x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of IDGXF?
Yes, most major brokerages offer fractional shares of Integrated Diagnostics Holdings plc (IDGXF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track IDGXF's earnings and financial reports?
Integrated Diagnostics Holdings plc (IDGXF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for IDGXF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.